Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TAC01-CD19
i
Other names:
TAC01-CD19, CD19 TAC, CD19-TAC01, TAC-921
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Triumvira
Drug class:
CD19 inhibitor
Related drugs:
‹
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
›
Associations
News
Trials
Filter by
Latest
over2years
TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Triumvira Immunologics, Inc. | N=36 --> 0 | Not yet recruiting --> Withdrawn
over 2 years ago
Enrollment change • Trial withdrawal
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAC01-CD19
over4years
TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=36, Not yet recruiting, Triumvira Immunologics, Inc. | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2021 --> Apr 2022
over 4 years ago
Clinical • Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAC01-CD19
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login